Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023

Executive Summary

After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.

You may also be interested in...



Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns

Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel